TY  - GEN
AU  - Zandberg,Dan P
AU  - Algazi,Alain P
AU  - Jimeno,Antonio
AU  - Good,James S
AU  - Fayette,Jérôme
AU  - Bouganim,Nathaniel
AU  - Ready,Neal E
AU  - Clement,Paul M
AU  - Even,Caroline
AU  - Jang,Raymond W
AU  - Wong,Stuart
AU  - Keilholz,Ulrich
AU  - Gilbert,Jill
AU  - Fenton,Moon
AU  - Braña,Irene
AU  - Henry,Stephanie
AU  - Remenar,Eva
AU  - Papai,Zsuzsanna
AU  - Siu,Lillian L
AU  - Jarkowski,Anthony
AU  - Armstrong,Jon M
AU  - Asubonteng,Kobby
AU  - Fan,Jean
AU  - Melillo,Giovanni
AU  - Mesía,Ricard
TI  - Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
SN  - 1879-0852
PY  - 2020///0504
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - therapeutic use
KW  - Antineoplastic Agents, Immunological
KW  - B7-H1 Antigen
KW  - metabolism
KW  - Biomarkers, Tumor
KW  - Female
KW  - Follow-Up Studies
KW  - Head and Neck Neoplasms
KW  - drug therapy
KW  - Humans
KW  - International Agencies
KW  - Lymphatic Metastasis
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Prognosis
KW  - Salvage Therapy
KW  - Squamous Cell Carcinoma of Head and Neck
KW  - Survival Rate
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
UR  - https://doi.org/10.1016/j.ejca.2018.11.015
ER  -